LONDON, June 22, 2026, 10:05 BST
- British American Tobacco shares rose about 0.4% to 4,356p, recovering less than one-third of Friday’s 1.43% loss.
- Friday’s volume reached 12.7 million shares, roughly 2.9 times the 50-day average, but the session also included the FTSE UK annual-review implementation.
- BAT’s latest repurchases were executed at an aggregate calculated average of about 4,531.7p—nearly 4% above Monday’s early price.
British American Tobacco (LSE: BATS) was quoted around 4,356p in delayed early London trading on Monday, up approximately 18p, or 0.41%, after Friday’s drop to 4,337p. The immediate move looks less like a reaction to new earnings information and more like a partial technical rebound after a high-volume index-rebalance session, with Monday’s confirmation that the buyback remains active providing support at the margin. The stock has recovered only about 30% of Friday’s 63p loss, so this is stabilization—not yet a confirmed reversal.
For LSE: BATS, Friday’s volume is the revealing detail. Turnover of 12.7 million shares was almost 2.9 times the 50-day average of 4.4 million. Yet FTSE Russell’s annual UK index review was implemented after Friday’s close and became effective Monday, forcing passive funds to reset holdings and weights across the index. BAT was not promoted or relegated, but the broader rebalancing means Friday’s volume cannot automatically be treated as pure fundamental selling.
Monday’s regulatory announcement showed BAT bought 494,286 shares between June 15 and June 18. Using the disclosed daily quantities and volume-weighted prices, the company spent approximately £22.4 million at a calculated aggregate average of 4,531.7p per share. Monday’s early quote was 3.9% below that level. It is not a guaranteed price floor, but lower prices allow each additional pound committed to the programme to cancel more shares.
At roughly 4,356p, BAT’s full £1.3 billion 2026 buyback could theoretically purchase about 29.8 million shares, equivalent to approximately 1.38% of the 2.166 billion voting shares outstanding after the latest cancellations. That calculation assumes the entire programme were executed at Monday’s price and excludes transaction costs, but it illustrates why the buyback becomes more accretive as the stock retreats.
Nothing in Monday’s filing changes the operating outlook issued on June 2. BAT still expects 2026 revenue and adjusted operating-profit growth at the lower ends of its respective 3%–5% and 4%–6% ranges, although New Category revenue is now forecast to grow in the mid-teens. Chief Executive Tadeu Marroco said, “I am pleased that our full-year delivery remains firmly on track.” Investors nevertheless marked the shares down sharply after that update because stronger Vuse and Velo expectations did not produce a group-wide guidance increase. BAT
The potential upside remains concentrated in the United States. Following the FDA’s shift toward enforcement discretion for certain unauthorised nicotine products, BAT is preparing flavoured Vuse products for the third quarter and an updated Velo pouch for August or September. Marroco called the opportunity “very high,” with BAT estimating that unlicensed US vape sales represent a market worth about £7 billion. The unanswered question is how quickly improved market access can translate into consolidated earnings rather than additional launch spending. Reuters
The cash-return arithmetic is unusually important at the present price. BAT’s declared annual distribution of 245.04p per share equates to a calculated yield of roughly 5.6% at 4,356p. Adding the full-year buyback’s approximately 1.4% value relative to the current £94 billion market capitalisation produces a headline programme-level shareholder-return rate near 7.0%. Buybacks are not guaranteed investment returns, however, and their benefit depends on execution price and future earnings. The next 61.26p quarterly instalment goes ex-dividend in London on July 9 and is scheduled for payment on August 14.
The stock remains about 18% below its May high of 5,326p, despite trading on a reported price-to-earnings ratio near 12.4 times and offering a dividend yield above 5.5%. That gap shows how quickly investors have reduced the premium attached to US regulatory relief: the market now wants evidence that policy changes improve profits, not merely the addressable market.
The balanced bear case is straightforward: BAT is still guiding only to the lower end of its medium-term growth ranges, cigarette value and volume shares have slipped in key markets, glo revenue is expected to decline at a low-double-digit rate, and currency translation could reduce adjusted EPS growth by 2%–3%. Technically, Friday’s 4,332p low is the immediate failure level; a sustained break would put the April area around 4,203p back into view. Traders should also adjust charts for the forthcoming 61.26p dividend, which alone represents about 1.4% of Monday’s price and will mechanically lower the reference price on July 9.
Monday’s intraday high of 4,376p is the first level bulls need to reclaim. Above that, 4,400p—the level immediately preceding Friday’s decline—would provide stronger evidence that index-related flows exaggerated the selling. Until then, the rebound remains small relative to the damage recorded over the previous three sessions.
The decisive catalyst is BAT’s July 30 half-year report. Investors will be looking for proof that Velo and Vuse momentum is reaching group profit, that the second-half weighting of earnings remains credible, and—most importantly—that management can move beyond the lower end of its 2026 guidance.
This article is provided for general informational purposes only and does not constitute investment, legal or tax advice, an offer, or a recommendation to buy or sell any security. Share prices and market conditions can change rapidly. Investors should conduct their own research and consider their objectives, financial circumstances and risk tolerance before making investment decisions.
